Independent Contribution of Diabetes to Increased Prevalence and Incidence of Atrial Fibrillation

GREGORY A. NICHOLS, PHD
KYNDAKON REINIER, PHD
SUMEET S. CHUGH, MD

OBJECTIVE — Diabetes has long been recognized as a risk factor for atrial fibrillation, but its independent contribution to atrial fibrillation has not been fully evaluated. We sought to compare the prevalence and incidence of atrial fibrillation in age- and sex-matched patients with and without type 2 diabetes.

RESEARCH DESIGN AND METHODS — Using an observational cohort design, we selected 10,213 members of an HMO diabetes registry as of 1 January 1999 plus 7,159 patients who entered the registry by 31 December 2004 and matched them to patients without diabetes on year of birth and sex. All patients were followed until they died, left the health plan, or until 31 December 2008. We compared the baseline prevalence of atrial fibrillation and then followed patients without atrial fibrillation to compare atrial fibrillation incidence while controlling for known risk factors.

RESULTS — Atrial fibrillation prevalence was significantly greater among patients with diabetes (3.6 vs. 2.5%, P < 0.0001). Over a mean follow-up of 7.2 ± 2.8 years, diabetic patients without atrial fibrillation at baseline developed atrial fibrillation at an age- and sex-adjusted rate of 9.1 per 1,000 person-years (95% CI 8.6–9.7) compared with a rate of 6.6 (6.2–7.1) among non-diabetic patients. After full adjustment for other risk factors, diabetes was associated with a 26% increased risk of atrial fibrillation among women (hazard ratio 1.26 [95% CI 1.08–1.46]), but diabetes was not a statistically significant factor among men (1.09 [0.96–1.24]).

CONCLUSIONS — In this population, diabetes was an independent determinant of atrial fibrillation prevalence but predicted incidence only among women. These findings have potential public health implications and emphasize the need for further investigation of the mechanistic links between diabetes and atrial fibrillation.

Diabetes Care 32:1851–1856, 2009

More than 23 million U.S. adults have diabetes (1), a figure that is growing by ~1 million each year (2). An additional 57 million U.S. residents are estimated to have pre-diabetes (1). Atrial fibrillation, the most common arrhythmia diagnosis in the world, afflicts approximately 2.2 million U.S. adults (3), and that number could more than double by 2050 (4). Other analyses have shown that the rising prevalence and incidence of atrial fibrillation cannot be explained by aging alone (5,6). Recent findings indicate that atrial fibrillation may be relatively common in diabetic patients and should be regarded as a marker of particularly adverse outcomes, prompting aggressive management of all risk factors (7). The overlap of diabetes and atrial fibrillation also contributes to a well-established increased risk of thromboembolic stroke (8).

Although diabetes and atrial fibrillation undoubtedly share common antecedents such as hypertension, atherosclerosis, and obesity (9–11), the confluence of these two conditions clearly warrants additional study. Diabetes has long been recognized as a risk factor for atrial fibrillation (12), which was subsequently reaffirmed in several studies (10,13,14). However, the potential independent contribution of diabetes to the prevalence and incidence of atrial fibrillation has not been evaluated. We therefore performed comparative analyses of the prevalence and incidence of atrial fibrillation in patients with and without diabetes.

RESEARCH DESIGN AND METHODS — The study site was Kaiser Permanente Northwest (KPNW), a 480,000-member group-model HMO that uses clinical practice guidelines to assist clinicians with patient management. We used an observational longitudinal study design that capitalizes on the comprehensive medical utilization data maintained by KPNW, including an electronic medical record of all patient encounters, laboratory results that are analyzed by a single regional laboratory using standardized methods, and dispenses from pharmacies located in all clinics. The institutional review board of the Kaiser Permanente Center for Health Research reviewed and approved the study.

Sample selection
Since 1989, KPNW has maintained a registry of patients with known diabetes. The criteria for registry entry include an inpatient or outpatient diagnosis of diabetes (ICD-9-CM codes 250.xx), use of an antihyperglycemic drug, or at least two blood glucose test results above diagnostic levels for diabetes. For the current study, we selected 10,213 patients who were members of the diabetes registry as of 1 January 1999 and 7,159 patients who entered the registry by 31 December 2004 (total = 17,372), defining the study index date as either 1 January 1999 (for pre-1999 registrants) or date of registry entry. We then matched these patients to KPNW members without diabetes on year of birth and sex. For these nondiabetic subjects, we defined their index date as that of their matched diabetic subject. The prevalence of atrial fibrillation was calculated as of the index date. To conduct incidence
analyses, we excluded patients with prevalent atrial fibrillation and 1,143 patients who had a history of stroke. The remaining patients were then followed until they died, left the health plan, or until 31 December 2008, whichever came first.

Outcomes and covariates

Patients were identified with prevalent atrial fibrillation if they had a diagnosis (ICD-9-CM 427.31) recorded in the medical record on or before their index date. Incident diagnoses were similarly identified any time after index until the end of follow-up among those patients who did not have prevalent atrial fibrillation. We also identified comorbidities present at baseline (ICD-9-CM code), including ischemic heart disease (410.x–414.x), history of stroke or cerebrovascular disease (430.x, 431.x, 432.x, 434.x, 435.x, 436.x, and 437.1), valvular disease (424.0–424.3), heart failure (428.x), hypertension (401.x–405.x), and history of depression (296.2x, 296.3x, 300.4, 309.1, and 311). Height, weight, and blood pressure were captured in the electronic medical record: for this study, baseline values of weight and blood pressure were the last measures before the index date. Baseline laboratory values, including LDL cholesterol, HDL cholesterol, triglycerides, serum creatinine (for estimation of glomerular filtration rate), and A1C (among patients with diabetes) were also those recorded latest on or before index date.

Statistical analyses

We conducted bivariate comparisons of baseline covariates among patients with and without diabetes using t tests for continuous variables and χ² tests for categorical variables. We calculated and compared age- and sex-adjusted incidence rates of atrial fibrillation per 1,000 person-years using regression for incidence densities. We then used Cox proportional hazards regression analysis to determine risk of incident atrial fibrillation for diabetes, controlling for other risk factors. All analyses were conducted with SAS (version 8.2; SAS Institute, Cary, NC).

RESULTS — Mean age of the study sample was 58.4 ± 11.5 years, and 51.2% were men (Table 1). Patients with diabetes were more likely to be nonwhite (11.9 vs. 6.4%, P < 0.0001), to have a higher BMI (33.6 ± 7.3 vs. 28.9 ± 5.7 kg/m², P < 0.0001), and to have higher blood pressure (136/80 vs. 132/79 mmHg, P < 0.0001). Comorbidities were more common among patients with diabetes, including ischemic heart disease (10.6 vs. 9.8%, P = 0.014), history of stroke (4.4 vs. 2.9%, P < 0.0001), hypertension (4.7 vs. 26.9%, P < 0.0001), heart failure (4.4 vs. 1.8%, P < 0.0001), and history of depression (15.8 vs. 11.7%, P < 0.0001).

The prevalence of atrial fibrillation was significantly greater among patients with diabetes (3.6 vs. 2.5%, P < 0.0001) (Fig. 1A). Prevalence increased with age in both groups but was significantly exaggerated among diabetic patients. These same relationships were observed among men (Fig. 1B) and women (Fig. 1C). Although men had a higher prevalence of atrial fibrillation in all age-groups regardless of diabetes, the difference in prevalence between those with and without diabetes was greater in women than in men. For example, among men aged 65–74 years, atrial fibrillation was 30% more prevalent among patients with diabetes (7.9 vs. 6.1%, P = 0.037). Among women, atrial fibrillation prevalence was 61% higher in diabetic patients in the 65–74 years age-group (6.1 vs. 3.8%, P = 0.002).

Over a mean follow-up of 7.2 ± 2.8 years, the 16,037 diabetic patients without prevalent atrial fibrillation or a history of stroke at baseline developed atrial fibrillation at an age- and sex-adjusted incidence rate of 9.1 per 1,000 person-years (95% CI 8.6–9.7) compared with a rate of 6.6 (6.2–7.1) among the 16,471 nondiabetic patients (Fig. 2A). Thus, the age- and sex-adjusted relative risk of atrial fibrillation was 38% (28–49%) greater among individuals with diabetes. Among men, the age-adjusted incidence of atrial fibrillation per 1,000 person-years was 10.8 (9.9–11.7) and 8.3 (7.6–9.1), respectively, for patients with and without diabetes (Fig. 1B), producing a 30% (17–43%) greater relative risk among men with diabetes. Among women, age-adjusted atrial fibrillation incidence was 7.6 (6.9–8.4) and 5.0 (4.5–5.6), respectively (Fig. 1C), with a higher relative risk attributable to diabetes of 52% (34–70%).

Table 2 displays the Cox regression models of time to development of atrial fibrillation. After controls were included for other known risk factors, patients with diabetes had a 16% greater risk of developing atrial fibrillation (hazard ratio [HR] 1.16 [95% CI 1.05–1.28]). However, atrial fibrillation risk associated with diabetes was substantially higher among women (1.26 [1.08–1.46]) and was not statistically significant among men (1.09 [0.96–1.24]). In addition, age ≥65 years tripled the risk of atrial fibrillation overall.
but had a greater effect among women, whereas BMI \( \geq 30 \text{ kg/m}^2 \) increased atrial fibrillation risk among men but was not a significant predictor in the women only model. White race, systolic blood pressure \( \geq 140 \text{ mmHg} \), ischemic heart disease, valvular disease, hypertension, and heart failure were all significantly associated with atrial fibrillation risk in both sexes.

**CONCLUSIONS** — In this observational, age- and sex-matched cohort, longitudinal study of 34,744 patients with and without diabetes, we found that atrial fibrillation was 44% more prevalent and 38% more likely to develop when diabetes was present. Controlling for other known risk factors such as hypertension and heart failure approximately halved the risk of incident atrial fibrillation. However, this finding differed between men and women. Diabetes was not a significant predictor of atrial fibrillation among men after controlling for other risk factors but was highly significant among women.

Recent studies have provided evidence of how comorbidities can have important modulatory effects on the progression and complications of atrial fibrillation (15). Thus far, studies evaluating the specific role of diabetes have been lacking. In the recent development of a risk score for atrial fibrillation, the Framingham Heart Study did not find diabetes to be a significant predictor of atrial fibrillation risk (16). This finding is contrary to a previous Framingham report that found diabetes to be a strong independent risk factor (10). Consistent with the latter study, our findings suggest that in the present population, diabetes made a significant contribution to the prevalence and incidence of atrial fibrillation, independent of other established risk factors such as hypertension and congestive heart failure. Although this result needs to be confirmed in other populations, there may be important public health implications. The steadily rising prevalence of diabetes may further increase the prevalence of atrial fibrillation, already the most common arrhythmia diagnosis around the globe. Conversely, any efforts made to prevent and treat diabetes may reduce the burden of atrial fibrillation.

**Potential mechanisms**

These findings also underscore the importance of understanding the mechanistic links responsible for this association. Published studies point to abnormalities of the autonomic nervous system as being an important mechanism in initiation and maintenance of atrial fibrillation. In observational clinical studies, initiation of atrial fibrillation episodes have been ascribed to variations in autonomic tone.
Similar associations with altered autonomic tone have been made in conditions such as sleep apnea (18). This work has been extended in a canine model of atrial fibrillation in which researchers have observed that discharges from the stellate ganglia and vagal nerves often precede the onset of paroxysmal atrial fibrillation (19). In fact, targeted ablation of these latter structures appears to prevent the onset of paroxysmal atrial fibrillation in dogs, and such therapies are being evaluated in humans (20–22). Analogous to the well-described peripheral autonomic neuropathy observed in diabetes, cardiac autonomic neuropathy is a serious but overlooked complication of diabetes (23,24). Taken together, these findings lend credence to the hypothesis that cardiac autonomic dysfunction may be an important mechanism for the increased propensity for atrial fibrillation in diabetes and warrants further careful study.

Limitations
An observational study has some inherent limitations. In a subgroup of patients, atrial fibrillation is an asymptomatic and paroxysmal phenomenon, such that it may escape detection unless it is observed incidentally. It is possible that patients with diabetes may be more likely to have electrocardiograms or ambulatory monitoring in the absence of symptomatic atrial fibrillation compared with nondiabetic patients. Conversely, diabetes is undiagnosed in ~25% of individuals (1), suggesting that the prevalence of diabetes may have been underestimated in this population. If so, we may be underestimating the effect of diabetes on increased prevalence of atrial fibrillation in this population. Finally, unmeasured

Figure 2—Cumulative age- and sex-adjusted incidence of atrial fibrillation by diabetes status among patients who did not have atrial fibrillation at baseline. A: Data for all subjects. B: Data for men only. C: Data for women only.
variables such as socioeconomic status, education, and alcohol intake could account for some of the differences we report.

Summary
In conclusion, in this population, diabetes was an independent determinant of atrial fibrillation prevalence and incidence. Prevalence was higher at baseline and there was an exaggerated increase of atrial fibrillation incidence over time in diabetic versus nondiabetic patients. Women with diabetes had an unexplained higher predilection for atrial fibrillation compared with men. These findings have potential public health implications, especially in women, and emphasize the need for further investigation of the mechanistic links between diabetes and atrial fibrillation.

Acknowledgments—S.S.C. is the Pauline and Harold Price Chair in Cardiac Electrophysiology Research at the Heart Institute, Cedars-Sinai Health System, Los Angeles, California.

No potential conflicts of interest relevant to this article were reported.

Parts of this study were presented in abstract form at the 30th annual meeting of the Heart Rhythm Society, Boston, Massachusetts, 13–16 May 2009, and at the 45th annual meeting of the European Association for the Study of Diabetes, 29 September–2 October 2009.

References
1. American Diabetes Association. Total prevalence of diabetes and pre-diabetes [article online]. 2009. Available from http://www.diabetes.org/diabetes-statistics/prevalence.jsp. Accessed 10 February 2009
2. American Diabetes Association: Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008;31:596–615
3. American Heart Association. Atrial fibrillation [article online], 2009. Available from http://www.americanheart.org/presenter.html?identifier=4451. Accessed 10 February 2009
4. Go AS, Hylek EM, Phillips KA, Chang YC, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults. National implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA 2001;285:2370–2375
5. Miyaska Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, Seward JB, Tsang TS. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006;114:119–125
6. Wolf PA, Benjamin EJ, Belanger AJ, Kannel WB, Levy D, D’Agostino RB. Secular trends in the prevalence of atrial fibrillation: the Framingham Heart Study. Am Heart J 1996;131:790–795
7. Du X, Ninomiya T, de Galan B, Abidar E, Chalmers J, Pillai A, Woodward M, Cooper M, Harrap S, Hamet P, Poulter N, Lip GYH, Patel A, ADVANCE Collaborative Group. Risk of cardiovascular events and effect of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. Eur Heart J 2009;30:1128–1135
8. Tsang TS, Petty GW, Barnes ME, O’Fallon WM, Bailey KR, Wiebers DO, Sicks JD, Christianson TJ, Seward JB, Gersh BJ. The prevalence of atrial fibrillation in incident stroke cases and matched population controls in Rochester, Minnesota: changes over three decades. J Am Coll Cardiol 2003;42:93–100
9. Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, D’Agostino RB, Massaro JM, Beiser A, Wolf PA, Benjamin EJ. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004;110:1042–1046
10. Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study. JAMA 1994;271:840–844
11. Nichols GA, Hillier TA, Brown JB. Progress from newly acquired impaired fasting glucose to type 2 diabetes. Diabetes Care 2007;30:228–233
12. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: the Framingham Study. N Engl J Med 1982;306:1018–1022
13. Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM, CHS Research Collaborative Group. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 1994;74:236–241
14. Psaty BM, Manolio TA, Kuller LH, Kronmal RA, Cushman M, Fried LP, White R, Furberg CD, Rautaharju PM. Incidence of and risk factors for atrial fibrillation in older adults. Circulation 1997;96:2455–2461
15. Jahangir A, Lee V, Friedman PA, Trusty JM, Hodge DO, Kopecky SL, Packer DL, Hammill SC, Shen WK, Gersh BJ. Long-term progression and outcomes with aging in patients with lone atrial fibrillation: a 30-year follow-up study. Circulation 2007;115:3050–3056
16. Schnabel RB, Sullivan LM, Levy D, Pencina MJ, Massaro JM, D’Agostino RB Sr, Newton-Cheh C, Yamamoto JF, Magnani JW, Tadros TM, Kannel WB, Wang TJ, Ellinor PT, Wolf PA, Vasan RS, Benjamin EJ. Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet 2009;373:739–745
17. Bettoni M, Zimmermann M. Autonomic tone variations before the onset of parox-

| Table 2—Cox regression analysis of time to atrial fibrillation among patients without atrial fibrillation or stroke at baseline |
| --- |
| **Men and women** | **Men only** | **Women only** |
| **HR (96% CI)** | **P** | **HR (96% CI)** | **P** | **HR (96% CI)** | **P** |
| Diabetes | 1.16 (1.05–1.28) | 0.003 | 1.09 (0.96–1.24) | 0.170 | 1.26 (1.08–1.46) | 0.003 |
| Age ≥65 years | 3.10 (2.81–3.43) | <0.001 | 2.69 (2.37–3.07) | <0.001 | 3.80 (3.24–4.46) | <0.001 |
| Male sex | 1.37 (1.24–1.50) | <0.001 | 1.58 (1.20–2.07) | 0.001 | 1.61 (1.18–2.19) | 0.002 |
| White race | 1.60 (1.30–1.96) | <0.001 | 1.29 (1.13–1.46) | <0.001 | 1.13 (0.97–1.31) | 0.115 |
| Ever smoked | 1.02 (0.91–1.15) | 0.751 | 1.02 (0.88–1.18) | 0.812 | 1.17 (1.01–1.35) | 0.032 |
| BMI ≥30 kg/m² | 1.22 (1.11–1.34) | <0.001 | 1.29 (1.13–1.46) | <0.001 | 1.93 (1.60–2.33) | <0.001 |
| Systolic blood pressure ≥140 mmHg | 1.24 (1.13–1.36) | <0.001 | 1.29 (1.13–1.46) | <0.001 | 2.40 (2.17–3.36) | <0.001 |
| Ischemic heart disease | 1.71 (1.53–1.93) | <0.001 | 1.62 (1.40–1.88) | <0.001 | 1.34 (1.15–1.55) | <0.001 |
| Valvular disease | 2.18 (1.73–2.74) | <0.001 | 2.05 (1.50–2.81) | <0.001 | 2.18 (1.68–2.82) | <0.001 |
| Hypertension | 1.32 (1.20–1.46) | <0.001 | 1.29 (1.13–1.46) | <0.001 | 1.29 (1.13–1.46) | <0.001 |
| Heart failure | 2.33 (1.95–2.78) | <0.001 | 2.39 (1.86–3.07) | <0.001 | 2.39 (1.86–3.07) | <0.001 |
ysmal atrial fibrillation. Circulation 2002; 105:2753–2759

18. Gami AS, Hodge DO, Herges RM, Olson EJ, Nykodym J, Kara T, Somers VK. Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation. J Am Coll Cardiol 2007;49:565–571

19. Ogawa M, Zhou S, Tan AY, Song J, Ghomieh G, Fishbein MC, Luo H, Siegel RJ, Karagueuzian HS, Chen LS, Lin SF, Chen PS. Left stellate ganglion and vagal nerve activity and cardiac arrhythmias in ambulatory dogs with pacing-induced congestive heart failure. J Am Coll Cardiol 2007;50:335–343

20. Tan AY, Zhou S, Ogawa M, Song J, Chu M, Li H, Fishbein MC, Lin SF, Chen LS, Chen PS. Neural mechanisms of paroxysmal atrial fibrillation and paroxysmal atrial tachycardia in ambulatory canines. Circulation 2008;118:916–925

21. Hou Y, Scherlag BJ, Lin J, Zhang Y, Lu Z, Truong K, Patterson E, Lazzara R, Jackman WM, Po SS. Ganglionated plexi modulate extrinsic cardiac autonomic nerve input: effects on sinus rate, atrioventricular conduction, refractoriness, and inducibility of atrial fibrillation. J Am Coll Cardiol 2007;50:61–68

22. Lemola K, Chartier D, Yeh YH, Dubuc M, Cartier R, Armour A, Ting M, Sakabe M, Shirosita-Takeshita A, Comtois P, Nattel S. Pulmonary vein region ablation in experimental vagal atrial fibrillation: role of pulmonary veins versus autonomic ganglia. Circulation 2008;117:470–477

23. Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care 2003;26:1553–1579

24. Valensi P, Sachs RN, Harfouche B, Lormeau B, Paries J, Cosson E, Paycha F, Leutenegger M, Attali JR. Predictive value of cardiac autonomic neuropathy in diabetic patients with or without silent myocardial ischemia. Diabetes Care 2001;24:339–343

25. Burke JH, Ehler FA, Kruse JT, Parker MA, Goldberger JJ, Kadish AH. Gender-specific differences in the QT interval and the effect of autonomic tone and menstrual cycle in healthy adults. Am J Cardiol 1997;79:178–181